Showing results (71-80 of 162) with videos related to
Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survivalElke De Bruyne, Tomas Jan Bos, Kewal Asosingh, et al.Oncotarget|December 31, 2015
Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cellsSusanne Lub, Anke Maes, Ken Maes, et al.Cancer Letters|March 22, 2022
System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistanceFang Wang, Inge Oudaert, Chenggong Tu, et al.Journal of Extracellular Vesicles|June 18, 2026
Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple MyelomaMichiel De Coster, Lukas Hyka, Sophie De Cock, et al.Cancer Immunology Research|September 15, 2017
Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine SecretionKim De Veirman, Nathan De Beule, Ken Maes, et al.Molecular Oncology|September 11, 2025
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolismInge Oudaert, Lauren van den Broecke, Osman Aksoy, et al.Oncotarget|April 15, 2015
Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cellsKim De Veirman, Jo A Van Ginderachter, Susanne Lub, et al.Oncotarget|July 11, 2014
The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimeticLiesbeth Bieghs, Susanne Lub, Karel Fostier, et al.Journal of Experimental & Clinical Cancer Research : CR|April 16, 2025
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapseCatharina Muylaert, Lien Ann Van Hemelrijck, Arne Van der Vreken, et al.Plos One|June 7, 2013
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma modelHaneen Nur, Karel Fostier, Sandrine Aspeslagh, et al.Pageof 17